Literature DB >> 28079013

Natural Product Inhibitors of Topoisomerases: Review and Docking Study.

Luciana Scotti1, Francisco Jaime Bezerra Mendonca2, Frederico Favaro Ribeiro3, Josean Fechine Tavares1, Marcelo Sobral da Silva1, Jose Maria Barbosa Filho1, Marcus Tullius Scotti1.   

Abstract

Since ancient times, natural products have been used in treating various diseases effectively and safely. Nowadays, these natural compounds are submitted to sophisticated methodologies from isolation, computing, analytical, and even serving as pharmacophore suggestions for synthesis. The substances extracted from marine species, plants, and microorganisms present activities beneficial to our health, including protection against malignant tumors. The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme inhibitors is an important target in the search for new anticancer drugs. This review discusses this problem, reporting research involving alkaloids, terpenes, flavonoids, xanthones, coumarins, acetogenins, and in addition, includes a docking study with our Brazilian diterpenes to topoisomerases I and II. The better compound, the trachylobane 1, forms one hydrogen bond when submitted to docking with Topo I (with the ASP533 residue) and two with residues in Topo II (THR213 and TYR188). The difference observed in the energy of formation can be attributed to hydrogen-bond interactions. The difference observed in the energy of formation can be attributed to hydrogen-bond interactions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alkaloids; cancer; docking; flavonoids; terpenes; topoisomerases

Mesh:

Substances:

Year:  2018        PMID: 28079013     DOI: 10.2174/1389203718666170111114442

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  6 in total

1.  Novel drug isolated from mistletoe (1E,4E)-1,7-bis(4-hydroxyphenyl)hepta-1,4-dien-3-one for potential treatment of various cancers: synthesis, pharmacokinetics and pharmacodynamics.

Authors:  Jing Hong; Lin Meng; Peipei Yu; Ceng Zhou; Zhaoyan Zhang; Zhiguo Yu; Feng Qin; Yunli Zhao
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

2.  Ginsenoside Rg3-loaded, reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury.

Authors:  Lan Li; Yili Wang; Rui Guo; Sheng Li; Jingyu Ni; Shan Gao; Xiumei Gao; Jingyuan Mao; Yan Zhu; Pingli Wu; Hongjun Wang; Deling Kong; Han Zhang; Meifeng Zhu; Guanwei Fan
Journal:  J Control Release       Date:  2019-11-26       Impact factor: 9.776

Review 3.  Recent developments in topoisomerase-targeted cancer chemotherapy.

Authors:  KirkE Hevener; Tatsiana A Verstak; Katie E Lutat; Daniel L Riggsbee; Jeremiah W Mooney
Journal:  Acta Pharm Sin B       Date:  2018-07-25       Impact factor: 11.413

4.  Discovery of novel natural products as dual MNK/PIM inhibitors for acute myeloid leukemia treatment: Pharmacophore modeling, molecular docking, and molecular dynamics studies.

Authors:  Linda M Mohamed; Maha M Eltigani; Marwa H Abdallah; Hiba Ghaboosh; Yousef A Bin Jardan; Osman Yusuf; Tilal Elsaman; Magdi A Mohamed; Abdulrahim A Alzain
Journal:  Front Chem       Date:  2022-07-22       Impact factor: 5.545

5.  Antifungal Activity of Mexican Propolis on Clinical Isolates of Candida Species.

Authors:  Claudia Rebeca Rivera-Yañez; Porfirio Alonso Ruiz-Hurtado; Julia Reyes-Reali; María Isabel Mendoza-Ramos; María Elena Vargas-Díaz; Karla Mariela Hernández-Sánchez; Glustein Pozo-Molina; Claudia Fabiola Méndez-Catalá; Gina Stella García-Romo; Alexander Pedroza-González; Adolfo René Méndez-Cruz; Oscar Nieto-Yañez; Nelly Rivera-Yañez
Journal:  Molecules       Date:  2022-09-01       Impact factor: 4.927

6.  Flavonoids as Putative Epi-Modulators: Insight into Their Binding Mode with BRD4 Bromodomains Using Molecular Docking and Dynamics.

Authors:  Fernando D Prieto-Martínez; José L Medina-Franco
Journal:  Biomolecules       Date:  2018-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.